2:01 PM · 20 December 2024

BREAKING: Novo Nordisk shares lose 20% amid weak performance by CagriSema🚨

Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

 

The company's shares are trading at their lowest since August 2023. Source: xStation 

10 July 2026, 2:21 PM

Meta Announces Its Own AI Chips. Is the Era of Full Dependence on NVIDIA Slowly Coming to an End?

10 July 2026, 12:39 PM

Vodafone shares surge 13% after Xavier Niel's £4.4 billion investment. What's next for the stock?

10 July 2026, 11:47 AM

🚩 Apollo Global warns on AI: Has the market become too optimistic?

9 July 2026, 4:49 PM

Stock of the Week: Seagate Technology. How an old technology found a new role in the era of artificial intelligence

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits